Literature DB >> 23572524

Integrin-binding protein nischarin interacts with tumor suppressor liver kinase B1 (LKB1) to regulate cell migration of breast epithelial cells.

Prachi Jain1, Somesh Baranwal, Shengli Dong, Amanda P Struckhoff, Rebecca A Worthylake, Suresh K Alahari.   

Abstract

Biallelic inactivation of LKB1, a serine/threonine kinase, has been detected in 30% of lung adenocarcinomas, and inhibition of breast tumor growth has been demonstrated. We have identified the tumor suppressor, Nischarin, as a novel binding partner of LKB1. Our mapping analysis shows that the N terminus of Nischarin interacts with amino acids 44-436 of LKB1. Time lapse microscopy and Transwell migration data show that the absence of both Nischarin and LKB1 from an invasive breast cancer cell line (MDA-MB-231) enhances migration as measured by increased distance and speed of migrating cells. Our data suggest that this is a result of elevated PAK1 and LIMK1 phosphorylation. Moreover, the absence of Nischarin and LKB1 increased tumor growth in vivo. Consistent with this, the percentage of S phase cells was increased, as demonstrated by flow cytometry and enhanced cyclin D1. The absence of Nischarin and LKB1 also led to a dramatic increase in the formation of lung metastases. Our studies, for the first time, demonstrate functional interaction between LKB1 and Nischarin to inhibit cell migration and breast tumor progression. Mechanistically, we show that these two proteins together regulate PAK-LIMK-Cofilin and cyclin D1/CDK4 pathways.

Entities:  

Keywords:  Breast Cancer; Migration; Protein Phosphorylation; Rho GTPases; Tumor Metastases

Mesh:

Substances:

Year:  2013        PMID: 23572524      PMCID: PMC3668711          DOI: 10.1074/jbc.M112.418103

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

1.  Enhanced expression of LKB1 in breast cancer cells attenuates angiogenesis, invasion, and metastatic potential.

Authors:  Zhi-Gang Zhuang; Gen-Hong Di; Zhen-Zhou Shen; Jian Ding; Zhi-Ming Shao
Journal:  Mol Cancer Res       Date:  2006-11       Impact factor: 5.852

2.  Generalized intestinal polyposis and melanin spots of the oral mucosa, lips and digits; a syndrome of diagnostic significance.

Authors:  H JEGHERS; V A McKUSICK; K H KATZ
Journal:  N Engl J Med       Date:  1949-12-29       Impact factor: 91.245

Review 3.  Molecular requirements for epithelial-mesenchymal transition during tumor progression.

Authors:  Margit A Huber; Norbert Kraut; Hartmut Beug
Journal:  Curr Opin Cell Biol       Date:  2005-10       Impact factor: 8.382

4.  LKB1 protein expression in human breast cancer.

Authors:  Hubert Fenton; Brian Carlile; Elizabeth A Montgomery; Hetty Carraway; James Herman; Fikret Sahin; Gloria H Su; Pedram Argani
Journal:  Appl Immunohistochem Mol Morphol       Date:  2006-06

5.  LIM kinase 1 increases tumor metastasis of human breast cancer cells via regulation of the urokinase-type plasminogen activator system.

Authors:  Rozita Bagheri-Yarmand; Abhijit Mazumdar; Aysegul A Sahin; Rakesh Kumar
Journal:  Int J Cancer       Date:  2006-06-01       Impact factor: 7.396

6.  Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase.

Authors:  D E Jenne; H Reimann; J Nezu; W Friedel; S Loff; R Jeschke; O Müller; W Back; M Zimmer
Journal:  Nat Genet       Date:  1998-01       Impact factor: 38.330

7.  The type III TGF-beta receptor suppresses breast cancer progression.

Authors:  Mei Dong; Tam How; Kellye C Kirkbride; Kelly J Gordon; Jason D Lee; Nadine Hempel; Patrick Kelly; Benjamin J Moeller; Jeffrey R Marks; Gerard C Blobe
Journal:  J Clin Invest       Date:  2006-12-07       Impact factor: 14.808

8.  The tumor suppressor LKB1 regulates lung cancer cell polarity by mediating cdc42 recruitment and activity.

Authors:  Shumin Zhang; Katherine Schafer-Hales; Fadlo R Khuri; Wei Zhou; Paula M Vertino; Adam I Marcus
Journal:  Cancer Res       Date:  2008-02-01       Impact factor: 12.701

9.  Increased risk for cancer in patients with the Peutz-Jeghers syndrome.

Authors:  L A Boardman; S N Thibodeau; D J Schaid; N M Lindor; S K McDonnell; L J Burgart; D A Ahlquist; K C Podratz; M Pittelkow; L C Hartmann
Journal:  Ann Intern Med       Date:  1998-06-01       Impact factor: 25.391

Review 10.  LKB1-dependent signaling pathways.

Authors:  Dario R Alessi; Kei Sakamoto; Jose R Bayascas
Journal:  Annu Rev Biochem       Date:  2006       Impact factor: 23.643

View more
  13 in total

1.  Nischarin inhibition alters energy metabolism by activating AMP-activated protein kinase.

Authors:  Shengli Dong; Somesh Baranwal; Anapatricia Garcia; Silvia J Serrano-Gomez; Steven Eastlack; Tomoo Iwakuma; Donald Mercante; Franck Mauvais-Jarvis; Suresh K Alahari
Journal:  J Biol Chem       Date:  2017-08-24       Impact factor: 5.157

Review 2.  Understanding the role of integrins in breast cancer invasion, metastasis, angiogenesis, and drug resistance.

Authors:  Hassan Yousefi; Mousa Vatanmakanian; Mojdeh Mahdiannasser; Ladan Mashouri; Nikhilesh V Alahari; Mohammad Rafiee Monjezi; Shahrzad Ilbeigi; Suresh K Alahari
Journal:  Oncogene       Date:  2021-01-08       Impact factor: 9.867

3.  Exosomes from Nischarin-Expressing Cells Reduce Breast Cancer Cell Motility and Tumor Growth.

Authors:  Mazvita Maziveyi; Shengli Dong; Somesh Baranwal; Ali Mehrnezhad; Rajamani Rathinam; Thomas M Huckaba; Donald E Mercante; Kidong Park; Suresh K Alahari
Journal:  Cancer Res       Date:  2019-01-11       Impact factor: 12.701

Review 4.  Role of Nischarin in the pathology of diseases: a special emphasis on breast cancer.

Authors:  Samuel C Okpechi; Hassan Yousefi; Khoa Nguyen; Thomas Cheng; Nikhilesh V Alahari; Bridgette Collins-Burow; Matthew E Burow; Suresh K Alahari
Journal:  Oncogene       Date:  2022-01-22       Impact factor: 9.867

5.  Expression of integrin-binding protein Nischarin in metastatic breast cancer.

Authors:  Jie Chen; Wei-Liang Feng; Wen-Ju Mo; Xiao-Wen Ding; Shang-Nao Xie
Journal:  Mol Med Rep       Date:  2015-02-18       Impact factor: 2.952

6.  Lovastatin overcomes gefitinib resistance through TNF-α signaling in human cholangiocarcinomas with different LKB1 statuses in vitro and in vivo.

Authors:  Sheng-Huei Yang; Hung-Yun Lin; Vincent H S Chang; Chien-Chung Chen; Yun-Ru Liu; Jinghan Wang; Keqiang Zhang; Xiaoqing Jiang; Yun Yen
Journal:  Oncotarget       Date:  2015-09-15

7.  Regulation of triple-negative breast cancer cell metastasis by the tumor-suppressor liver kinase B1.

Authors:  L V Rhodes; C R Tate; V T Hoang; H E Burks; D Gilliam; E C Martin; S Elliott; D B Miller; A Buechlein; D Rusch; H Tang; K P Nephew; M E Burow; B M Collins-Burow
Journal:  Oncogenesis       Date:  2015-10-05       Impact factor: 7.485

8.  A mutation in Nischarin causes otitis media via LIMK1 and NF-κB pathways.

Authors:  Michael Crompton; Tom Purnell; Hayley E Tyrer; Andrew Parker; Greg Ball; Rachel E Hardisty-Hughes; Richard Gale; Debbie Williams; Charlotte H Dean; Michelle M Simon; Ann-Marie Mallon; Sara Wells; Mahmood F Bhutta; Martin J Burton; Hilda Tateossian; Steve D M Brown
Journal:  PLoS Genet       Date:  2017-08-14       Impact factor: 5.917

9.  PAK2 is an effector of TSC1/2 signaling independent of mTOR and a potential therapeutic target for Tuberous Sclerosis Complex.

Authors:  Maria M Alves; Gwenny M Fuhler; Karla C S Queiroz; Jetse Scholma; Susan Goorden; Jasper Anink; C Arnold Spek; Marianne Hoogeveen-Westerveld; Marco J Bruno; Mark Nellist; Ype Elgersma; Eleonora Aronica; Maikel P Peppelenbosch
Journal:  Sci Rep       Date:  2015-09-28       Impact factor: 4.379

10.  Inhibition of Nischarin Expression Promotes Neurite Outgrowth through Regulation of PAK Activity.

Authors:  Yuemin Ding; Yuying Li; Lingchao Lu; Ruyi Zhang; Linghui Zeng; Linlin Wang; Xiong Zhang
Journal:  PLoS One       Date:  2015-12-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.